Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism (Q41529400)

2 October 2017

1 reference

title

Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism (English)

1 reference

2 October 2017

F. Z. Stanczyk

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9220223

6 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9220223

6 November 2024

publication date

1 May 1997

1 reference

2 October 2017

May 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9220223

full work available at URL

6 November 2024

https://api.elsevier.com/content/article/PII:S0010782497000309?httpAccept=text/xml

1 reference

10.1016/S0010-7824(97)00030-9

DOI

https://api.crossref.org/works/10.1016/S0010-7824(97)00030-9

https://api.elsevier.com/content/article/PII:S0010782497000309?httpAccept=text/plain

6 November 2024

1 reference

10.1016/S0010-7824(97)00030-9

DOI

https://api.crossref.org/works/10.1016/S0010-7824(97)00030-9

6 November 2024

1 reference

2 October 2017

volume

55

1 reference

2 October 2017

issue

5

1 reference

2 October 2017

page(s)

273-282

1 reference

Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Biotransformation of norgestimate in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Radioimmunoassay of a new progestagen, Org 2969, and its metabolite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Metabolism of a new synthetic progestagen, Org 2969, by human liver in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Potency and pharmacokinetics of gestagens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Single dose pharmacokinetics of gestodene in women after intravenous and oral administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Gestodene: a novel synthetic progestin--characterization of binding to receptor and serum proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Comparative pharmacology of newer progestogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combinatio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Concentration of Ethinyl Estradiol in the Serum of 31 Young Women following a Treatment Period of 3 Months with Two Low-Dose Oral Contraceptives in an Intraindividual Cross-Over Design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2897%2900030-9

10.1016/S0010-7824(97)00030-9

7 January 2021

Identifiers

DOI

1 reference

2 October 2017

1 reference